Ginkgo Bioworks Holdings (DNA) Net Margin (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Net Margin of 33.52% for Q1 2026, up 86.14% on a QoQ basis from 241.8% in Q4 2025, and down 1352.0% year-over-year from 2.68% in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Net Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Net Margin history runs 7 years deep, the most recent figure standing at 33.52% for Q1 2026.
- Quarterly Net Margin fell 1352.0% year-over-year to 33.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 161.58% (up 943.0% YoY) and the FY2025 annual result came in at 183.81%, up 5713.0% from the prior year.
- Net Margin was 33.52% for Q1 2026 at Ginkgo Bioworks Holdings, up from 241.8% in the prior quarter.
- Across five years, Net Margin topped out at 20.0% in Q1 2025 and bottomed at 1009.26% in Q3 2022.
- A 5-year average of 285.85% and a median of 241.8% in 2025 frame the typical range for Net Margin.
- Peak annual rise in Net Margin reached 90475 bps in 2022, while the deepest fall reached 87732 bps in 2022.
- Ginkgo Bioworks Holdings' Net Margin stood at 176.1% in 2022, then soared by 51 bps to 87.09% in 2023, then tumbled by 182 bps to 245.25% in 2024, then advanced by 1 bps to 241.8% in 2025, then surged by 86 bps to 33.52% in 2026.
- Business Quant data shows DNA's Net Margin at 33.52% in Q1 2026, 241.8% in Q4 2025, and 207.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -33.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.52% |
| Dec 31, 2025 | -241.80% |
| Sep 30, 2025 | -207.93% |
| Jun 30, 2025 | -121.56% |
| Mar 31, 2025 | -20.00% |
| Dec 31, 2024 | -245.25% |
| Sep 30, 2024 | -63.34% |
| Jun 30, 2024 | -386.40% |
| Mar 31, 2024 | -437.25% |
| Dec 31, 2023 | -87.09% |
| Sep 30, 2023 | -546.44% |
| Jun 30, 2023 | -215.12% |
| Mar 31, 2023 | -253.98% |
| Dec 31, 2022 | -176.10% |
| Sep 30, 2022 | -1,009.26% |
| Jun 30, 2022 | -463.68% |
| Mar 31, 2022 | -350.65% |
| Dec 31, 2021 | -1,080.85% |
| Sep 30, 2021 | -131.95% |
| Jun 30, 2021 | -124.81% |